Venk Group

Venkatesh Thiruganasambandamoorthy profile picture

Contact Information

Venkatesh Thiruganasambandamoorthy, MBBS, CCFP-EM, MSc
613-998-5555 x17023

Bahareh Ghaedi
Research Coordinator
613-798-5555 x19347

Research Activities

  1.  Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients after Discharge: REMOSYNC Study – Pilot Study
    The purpose of the REMOSYNC Study is to evaluate the diagnostic yield of a 15-day remote cardiac event monitor among high-risk syncope patients discharged home. We believe the results of our study will lead to prolonged ambulatory cardiac monitoring as the standard of care for syncope patients at-risk for arrhythmias. Once the effectiveness of remote cardiac monitoring is established, this strategy can be applied to syncope patients who are hospitalized solely for the purposes of cardiac monitoring to reduce hospitalizations.
  2. Validation of the Canadian Syncope Risk Score
    This multicenter study aims to prospectively validate the performance of the Canadian Syncope Risk Score in a new cohort of ED patients. Once validated, the tool will be able to accurately stratify the risk of serious adverse events among patients presenting with syncope, including those at low risk who can be discharged home quickly.
  3. Prospective Multicentre Risk Stratification of Adult ED Syncope
    This study was conducted at 6 academic Emergency Departments (ED) to derive a risk tool for patients who present to the ED with syncope. Using data from 4,030 patients, we developed the Canadian Syncope Risk Score which showed good discrimination and calibration for 30-day risk of serious adverse events after disposition from the ED.
  4. Improving care of Patients with Acute Cardiac Emergencies: Presyncope
    The prospective presyncope study at The Ottawa Hospital (Civic and General Campus) found the majority of patients with Serious Adverse Events (SAEs) after ED disposition are discharged home with no follow-up. We will conduct an observational cohort study to assess the usefulness of the risk scale in indentifying high-risk ED presyncope patients. 
  5. Role of Biomarker N-Terminal proBNP in Predicting Serious Adverse Events
    Through a multicentre sub-study of 1,339 patients, we found the level of biomarker N-Terminal proBNP (NT-proBNP) multicentre is predictive of Serious Adverse Events (such as death, arrhythmia, myocardial infarction, structural heart disease, pulmonary embolism, subarachnoid or significant hemorrhage) after ED disposition. Analysis of BNP levels were significantly higher among patients with cardiac and non-cardiac serious conditions not identified in the ED.
  6. Emergency Department Chest Pain Study
    The new generation of troponin assays has increased sensitivity and has the potential to detect non-ST elevation myocardial infarction as early as 2 hours after ED arrival. Due to their improved sensitivity, they are also elevated in other conditions that lead to minor cardiac damage (i.e. syncope, shortness of breath, sepsis). The overall goal of this study to improve the safety and efficiency of ED management of chest pain patients by optimal use of contemporary cardiac troponin I (TnI) assay. At the end of phase I, we plan to develop guidelines that determine the absolute TnI levels or change in levels from 0 to 3 hours after ED arrival for classifying ED chest pain patients. This is being conducted at the Ottawa Hospital (Civic and General) and we believe the results of this study will lead to significant improvements in quality of patient care, efficiency, and ED and hospital overcrowding.